Admission hypoxia-inducible factor 1α levels and in-hospital mortality in patients with acute decompensated heart failure

BMC Cardiovascular Disorders

Zhong-zhi Tang¹  Zi-hua Zhou³  Rong Ai²  Jian Cheng¹  Xiao-wei Wu⁴  Wei-hua Lu¹  Gang Li¹ 

[1] Emergency Department, Wuhan General Hospital of Guangzhou Military Command, Wuhan 430074, China;College of Foreign Language, Huazhong Agriculture University, Wuhan, China;Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China;Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China

关键词: In-hospital mortality;    N-terminal–pro-brain natriuretic peptide;    Acute decompensated heart failure;    Hypoxia-inducible factor 1α;   

Others  :  1221380
DOI  :  10.1186/s12872-015-0073-6

 received in 2015-03-11, accepted in 2015-07-24,  发布年份 2015

【 摘 要 】

Background

Hypoxia-inducible factor 1 (HIF-1) is a critical regulator for cellular oxygen balance. Myocardial hypoxia can induce the increased expression of HIF-1α. Our goals were to evaluate the value of HIF-1α in predicting death of patients with acute decompensated heart failure (ADHF) and describe the in vivo relationship between serum HIF-1α and N-terminal–pro-brain natriuretic peptide (NT-proBNP) levels.

Method

We included 296 patients who were consecutively admitted to the emergency department for ADHF. The primary end point was in-hospital death. The patients were categorized as HFrEF (patients with reduced systolic function) and HFpEF (patients with preserved systolic function) groups.

Results

In our patients, the median admission HIF-1α level was 2.95 ± 0.85 ng/ml. The HIF-1α level was elevated significantly in HFrEF patients and deceased patients compared with HFpEF patients and patients who survived. The HIF-1α level was positively correlated with NT-proBNP and cardiac troponin T levels, and negatively correlated with left ventricular ejection fraction and systolic blood pressure. Kaplan–Meier curves revealed a significant increase in in-hospital mortality in ADHF patients with higher HIF-1α levels. Multivariable Cox regression analysis showed that HIF-1α levels were not correlated with the short-term prognosis of ADHF patients.

Conclusions

This is the first study to evaluate the circulating levels of HIF-1α in ADHF patients. Serum HIF-1α levels may reflect a serious state in patients with ADHF. Due to the limitations of the study, serum HIF-1α levels were not correlated with the in-hospital mortality based on regression analysis. Further studies are needed to demonstrate the diagnostic and/or prognostic role of HIF-1α as a risk biomarker in patients with ADHF.

【 授权许可】

   
2015 Li et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Lehman JJ, Kelly DP: Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 2002, 7:175-185.
• [2]Taegtmeyer H, Golfman L, Sharma S, van Arsdall M: Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann NY Acad Sci 2004, 1015:202-213.
• [3]Levy D, Garrison RJ, Savage DD, DannelWB CWP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990, 322:1561-1566.
• [4]Frohlich ED, Apstein C, Chobanian AV, Devereaux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus SM, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C: The heart in hypertension. N Engl J Med 1992, 327:998-1008.
• [5]Semenza GL: HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013, 123:3664.
• [6]Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC, Larsen T, Pedrazzini T, Krek W: Activation of a HIF-1α-PPARγ axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009, 9:512-524.
• [7]Semenza GL: Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 2014, 76:39-56.
• [8]Semenza GL: Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harbor symposia on quantitative biology. Cold Spring Harb Perspect Biol 2011, 76:347-353.
• [9]Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, Darshan MS, Gonzalez FJ, Semenza GL: Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci 2012, 109:10504-10509.
• [10]Cai Z, Luo W, Zhan H, Semenza GL: Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci 2013, 110:17462-17467.
• [11]Semenza GL: Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
• [12]Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu L, Asahara T, Hamada H, Tomita D, Molkentin JD, Zou Y, Komuro I: p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
• [13]Clerico A, Giannoni A, Vittorini S, Passino C: Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301:H12-H20.
• [14]Goetze JP: Biosynthesis of cardiac natriuretic peptides. Results Probl Cell Differ 2010, 50:97-120.
• [15]Del Ry S, Cabiati M, Clerico A: Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure. Pharmacol Res 2013, 76:190-198.
• [16]Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M: Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007, 49:1943-1950.
• [17]Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H: B-type natriuretic peptide–guided heart failure therapy a meta-analysis BNP-guided heart failure therapy. Arch Intern Med 2010, 170:507-514.
• [18]Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacheret R: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
• [19]Casals G, Ros J, Sionis A, Davidson MM, Jiménez MM: Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol 2009, 297:550-555.
• [20]Weidemann A, Klanke B, Wanger M, Volk T, Willam C, Michael S, Wiesener MS, Eckardt KU, Warnecke C: Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1α, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 2008, 409:233-242.
• [21]Arjamaa O, Nikinmaa M: Hypoxia regulates the natriuretic peptide system. Int J Physiol Pathophysiol Pharmacol 2011, 3:191-201.
• [22]Chun YS, Hyun JY, Kwak YG, Kim IS, Kim CH, Choi E, Kim MS, Park JW: Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003, 370:149-157.
• [23]Wilhide ME, Jones WK: Potential therapeutic gene for the treatment of ischemic disease: Ad2/hypoxia-inducible factor-1α (HIF-1)/VP16 enhances B-type natriuretic peptide gene expressionvia a HIF-1-responsive element. Mol Pharmacol 2006, 69:1773-1778.
• [24]McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A: ESC Committee for Practice Guidelines: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 33:1787-1847.
• [25]Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL: American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
• [26]Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R: Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem 2004, 41:459-463.
• [27]Mingles A, Jacobs L, Michelson E, Swedenborg J, Wooding W, van Diejien-Visser M: Reference population and marathon runners sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009, 55:101-108.
• [28]Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quiñoneset M: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009, 22:1-23.
• [29]Robador PA, San José G, Rodríguez C, Guadall A, Moreno MU, Beaumont J, Fortuño A, Díez J, Martínez-González J, Zalba G: HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovasc Res 2011, 92:247-255.
• [30]Semenza GL: Oxygen sensing, homeostasis, and disease. N Engl J Med 2011, 365:537-547.
• [31]Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001, 13:167-171.
• [32]Huang LE, Gu J, Schau M, Bunn HF: Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 1998, 95:7987-7992.
• [33]Chavez JC, Agani F, Pichiule P, LaManna JC: Expression of hypoxia-inducible factor-1 alpha in the brain of rats during chronic hypoxia. J Appl Physiol 2000, 89:1937-1942.
• [34]Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ: The relationship between serum hypoxia-inducible factor 1alpha and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc Diabetol 2014, 13:52. BioMed Central Full Text
• [35]Beyer C, Stearns NA, Giessl A, Distler JHW, Schett G, Pisetsky DS: The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate immun 2012, 18:727-737.
• [36]Yu X, Deng L, Wang D, Li N, Chen X, Cheng X, Yuan J, Gao X, Liao M, Wang M, Liao YH: Mechanism of TNF-α autocrine effects in hypoxic cardiomyocytes: Initiated by hypoxia inducible factor 1α, presented by exosomes. J Mol Cell Cardiol 2012, 53:848-857.
• [37]Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS: Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
• [38]Werno C, Menrad H, Weigert A, Dehne N, Goerdt S, Schledzewski K, Kzhyshkowska J, Brüne B: Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis 2010, 31:1863-1872.
• [39]Tekin D, Dursun AD, Xi L: Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin 2010, 31:1085-1094.
• [40]Silter M, Kögler H, Zieseniss A, Wilting J, Schäfer K, Toischer K, Katschinski DM: Impaired Ca2 + −handling in HIF-1α+/− mice as a consequence of pressure overload. Pflugers Arch 2010, 459:569-577.
• [41]Zhang H, Qiana DZ, Tana YS, Lee KA, Gao P, Rene YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL: Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci 2008, 105:19579-19586.